BR112017010953A2 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BR112017010953A2
BR112017010953A2 BR112017010953A BR112017010953A BR112017010953A2 BR 112017010953 A2 BR112017010953 A2 BR 112017010953A2 BR 112017010953 A BR112017010953 A BR 112017010953A BR 112017010953 A BR112017010953 A BR 112017010953A BR 112017010953 A2 BR112017010953 A2 BR 112017010953A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compound
carrier
biocompatible nanoparticle
individual
need
Prior art date
Application number
BR112017010953A
Other languages
English (en)
Other versions
BR112017010953B1 (pt
Inventor
Pottier Agnès
Levy Laurent
Meyre Marie-Edith
Germain Matthieu
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of BR112017010953A2 publication Critical patent/BR112017010953A2/pt
Publication of BR112017010953B1 publication Critical patent/BR112017010953B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a uma composição farmacêutica que compreende a combinação de (i) pelo menos uma nanopartícula biocompatível e de (ii) pelo menos um carreador que compreende pelo menos um composto farmacêutico, a ser administrada a um indivíduo que precisa de tal composto farmacêutico, em que a combinação da pelo menos uma nanopartícula biocompatível e do pelo menos um carreador que compreende o(s) composto(s) farmacêutico(s) potencializa a eficiência do(s) composto(s) de interesse. a dimensão mais longa da nanopartícula biocompatível está, tipicamente, entre cerca de 4 e cerca de 500 nm e seu valor de carga de superfície absoluto é de pelo menos 10 mv (|10 mv|). o carreador é, além disso, desprovido de qualquer agente de estabilização de superfície estericamente. a invenção se refere também a tal composição para uso para administração do(s) composto(s) farmacêutico(s) a um indivíduo que precisa do(s) mesmo(s), em que pelo menos uma nanopartícula biocompatível e pelo menos um carreador que compreende pelo menos um composto farmacêutico devem ser administrados separadamente a um indivíduo que precisa do dito composto farmacêutico, tipicamente entre mais de 5 minutos e cerca de 72 horas um do outro.
BR112017010953-0A 2014-11-25 2015-11-24 Composição farmacêutica contendo a combinação de um lipossoma e um carreador que compreende um composto farmacêutico BR112017010953B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306875 2014-11-25
EP14306875.7 2014-11-25
PCT/EP2015/077425 WO2016083333A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (2)

Publication Number Publication Date
BR112017010953A2 true BR112017010953A2 (pt) 2018-02-14
BR112017010953B1 BR112017010953B1 (pt) 2024-01-16

Family

ID=52013982

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010953-0A BR112017010953B1 (pt) 2014-11-25 2015-11-24 Composição farmacêutica contendo a combinação de um lipossoma e um carreador que compreende um composto farmacêutico

Country Status (23)

Country Link
US (1) US10765632B2 (pt)
EP (2) EP4431155A2 (pt)
JP (1) JP6789960B2 (pt)
KR (1) KR102666251B1 (pt)
CN (1) CN107106703A (pt)
AR (1) AR102782A1 (pt)
AU (1) AU2015352685B2 (pt)
BR (1) BR112017010953B1 (pt)
CA (1) CA2968919C (pt)
DK (1) DK3236934T3 (pt)
EA (1) EA201791147A1 (pt)
ES (1) ES2982895T3 (pt)
FI (1) FI3236934T3 (pt)
HK (1) HK1245085A1 (pt)
IL (2) IL252462B (pt)
LT (1) LT3236934T (pt)
MX (2) MX2017006812A (pt)
NZ (1) NZ769187A (pt)
PT (1) PT3236934T (pt)
SG (1) SG11201704219UA (pt)
TW (1) TW201628656A (pt)
UA (1) UA123665C2 (pt)
WO (1) WO2016083333A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116380C2 (uk) * 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
HUE062561T2 (hu) 2014-11-25 2023-11-28 Curadigm Sas Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai
ES2774365T3 (es) 2014-11-25 2020-07-20 Curadigm Sas Composición farmacéutica, preparación y usos de la misma
ES2890662T3 (es) 2014-11-25 2022-01-21 Curadigm Sas Composiciones farmacéuticas, preparación y usos de las mismas
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
NZ540778A (en) * 2002-12-31 2008-04-30 Zydus Bsv Res And Dev Private Non-pegylated long-circulating liposomes
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (en) * 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
WO2005086639A2 (en) 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20060264804A1 (en) * 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
WO2006127962A2 (en) * 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Particulate formulations for intradermal delivery of biologically active agents
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
EP2000150B1 (en) * 2006-03-24 2016-07-13 Toto Ltd. Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle
US20100233219A1 (en) 2006-03-30 2010-09-16 Fujifilm Corporation Inorganic nanoparticle compromising an active substance immobilized on the surface and a polymer
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
MX2010002100A (es) * 2007-08-21 2010-03-26 Alza Corp Composiciones de liposomas para administracion in vivo de compuestos de acido boronico.
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US20100272639A1 (en) 2007-12-21 2010-10-28 John Robert Dutcher Polysaccharide nanoparticles
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
KR101786142B1 (ko) 2010-03-26 2017-10-17 아브락시스 바이오사이언스, 엘엘씨 간세포 암종의 치료 방법
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
JP5713311B2 (ja) * 2010-09-24 2015-05-07 国立大学法人名古屋大学 リポソーム複合体、その製造方法、及びその使用
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
US20140227343A1 (en) * 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
DK2670394T3 (en) 2011-01-31 2019-01-14 Nanobiotix NANOPARTICLE DELIVERY SYSTEMS, PREPARATION AND APPLICATIONS THEREOF
US10251841B2 (en) 2011-10-17 2019-04-09 Trustees Of Boston University Polymeric depots for localization of agent to biological sites
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
HUE062561T2 (hu) 2014-11-25 2023-11-28 Curadigm Sas Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai
ES2890662T3 (es) 2014-11-25 2022-01-21 Curadigm Sas Composiciones farmacéuticas, preparación y usos de las mismas
ES2774365T3 (es) 2014-11-25 2020-07-20 Curadigm Sas Composición farmacéutica, preparación y usos de la misma
TW201628639A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途

Also Published As

Publication number Publication date
KR102666251B1 (ko) 2024-05-27
NZ732995A (en) 2021-01-29
ES2982895T3 (es) 2024-10-18
JP2017538783A (ja) 2017-12-28
UA123665C2 (uk) 2021-05-12
AR102782A1 (es) 2017-03-22
IL252462B (en) 2022-03-01
LT3236934T (lt) 2024-08-26
WO2016083333A1 (en) 2016-06-02
CN107106703A (zh) 2017-08-29
CA2968919C (en) 2023-07-18
BR112017010953B1 (pt) 2024-01-16
TW201628656A (zh) 2016-08-16
US20170258721A1 (en) 2017-09-14
EP4431155A2 (en) 2024-09-18
HK1245085A1 (zh) 2018-08-24
SG11201704219UA (en) 2017-06-29
FI3236934T3 (fi) 2024-07-22
KR20170093860A (ko) 2017-08-16
AU2015352685B2 (en) 2020-09-17
MX2021010595A (es) 2021-09-23
JP6789960B2 (ja) 2020-11-25
IL252462A0 (en) 2017-07-31
IL290114A (en) 2022-03-01
NZ769187A (en) 2023-07-28
EP3236934B1 (en) 2024-05-22
CA2968919A1 (en) 2016-06-02
DK3236934T3 (da) 2024-08-19
MX2017006812A (es) 2018-02-12
US10765632B2 (en) 2020-09-08
EP3236934A1 (en) 2017-11-01
PT3236934T (pt) 2024-08-01
AU2015352685A1 (en) 2017-07-13
EA201791147A1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
BR112015029853A2 (pt) uso de uma composição farmacêutica
BR112017010933A2 (pt) composição farmacêutica
BR112017010953A2 (pt) composição farmacêutica
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2016001547A1 (es) Composiciones para el cuidado oral
AR098882A1 (es) Composición dentífrica que comprende óxido de zinc y citrato de zinc
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112015022047A8 (pt) uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina
DOP2014000301A (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estatina
AR102780A1 (es) Composiciones farmacéuticas, su preparación y sus usos
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112015026238A8 (pt) composto dihidropirazino-pirazina, composição farmacêutica que o compreende, uso do composto, métodos para inibir ou medir a fosforilação e para inibir a atividade da proteína quinase, bem como kit
BR112012020989A2 (pt) composições veterinárias
BR112016015851A2 (pt) Formulações farmacêuticas estabilizadas de insulina aspart
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
BR112015021112A2 (pt) composições farmacêuticas que compreendem everolimo
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
BR112017027887A2 (pt) partículas e suspensões radioterapêuticas
AR112448A1 (es) Derivados de xantina sustituidos
BR102015006886B8 (pt) Composição tópicas que compreendem 4-hexilresorcinol e pós e uso
BR112015022484A2 (pt) formulações com oxidação reduzida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B25A Requested transfer of rights approved

Owner name: CURADIGM SAS (FR)

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2015, OBSERVADAS AS CONDICOES LEGAIS